Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
China Pharmacy ; (12): 280-284, 2023.
Article in Chinese | WPRIM | ID: wpr-961658

ABSTRACT

OBJECTIVE To analyze the status quo of performance appraisal of pharmacy intravenous admixture services (PIVAS) in China based on literature analysis, and provide reference for the implementation of performance management of PIVAS in China. METHODS Retrieved from domestic and foreign databases such as CNKI, VIP, Wanfang, PubMed, Embase, the Cochrane Library and CBM, the literature on the status quo evaluation of performance appraisal of PIVAS in China was included from the inception to Sept. 2022. The descriptive analysis was carried out on performance appraisal measures, performance appraisal indicators, performance appraisal achievement, etc. RESULTS Twelve pieces of literature were included, involving 8 before-and-after controlled studies and 4 experience sharing. The performance appraisal subjects of 10 pieces of literature were all staff and those of 2 pieces of literature were nurses. The measures of PIVAS performance appraisal were roughly the same, mainly involving contents and indicators of workload, work quality (including errors), clinical service satisfaction, labor discipline, department contribution, personal comprehensive evaluation, and so on, but the main accounting proportion was different. Performance appraisal indicators mainly included the rate of medical order review, dispensing rate, check rate, delivery rate, finished product review rate, etc. The performance appraisal achievement mainly included the improvement of work efficiency, the improvement of work quality, the reduction of error rate, and the improvement of clinical satisfaction and employee satisfaction. CONCLUSIONS By building performance appraisal system and adopting corresponding performance management measures of PIVAS, it can improve the work efficiency and quality, reduce the error rate, ensure the safety of patients’ medication, and promote the standardized management of PIVAS in China.

SELECTION OF CITATIONS
SEARCH DETAIL